Declarations of pharma funding are still not transparent enough, say criticsBMJ 2020; 371 doi: https://doi.org/10.1136/bmj.m4696 (Published 01 December 2020) Cite this as: BMJ 2020;371:m4696
- Lynn Eaton
- London, UK
Exact details of the £542.9m (€605.8m; $725m) that drug companies spent on healthcare organisations and healthcare professionals in 2019 have been disclosed—five months later than planned, as a direct result of the covid-19 pandemic.
The Association of British Pharmaceutical Industries (ABPI) has been publishing its annual summary of pharmaceutical companies’ spending since 2016, following criticism about the industry’s lack of transparency.
Although some of the figures were published in June,1 the detailed breakdown was delayed for the NHS to check the accuracy of the data before they are published.
The figures show that the bulk of funding from companies went towards research and development by organisations or individuals—£381.9m or 70% of the total …